Barbara White
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Latest Publications
- 1 May 2003
- Published by Elsevier in Rheumatic Disease Clinics of North America
- Vol. 29 (2) , 371-390
Interstitial lung disease in scleroderma
- 1 May 2003
- Published by Elsevier in Rheumatic Disease Clinics of North America
- Vol. 29 (2) , 371-390
Interstitial lung disease in scleroderma
- 1 March 2002
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 4 (2) , 108-112
Evaluation and management of pulmonary fibrosis in scleroderma
Pulmonary fibrosis causes significant morbidity and mortality in patients with scleroderma. Lung inflammation identifies patients at greater risk for decline in forced vital capacity and diffusing capacity for carbon monoxide. Factors that are increased in patients with scleroderma with lung fibrosis include connective tissue growth factor, KL-6, pulmonary surfactant-D, tissue inhibitor of metalloproteinase 2, monocyte chemotactic protein-1, macrophage inhibitory protein-1α, soluble interleukin-6 receptors, antiendothelial cell antibodies, and anti-DNA topoisomerase I antibodies. Potential mechanisms of lung damage in scleroderma include increased production of profibrotic type 2 cytokines and abnormal signaling by thrombin of tenascin-C production by lung fibroblasts, with protein kinase Cε as an intermediate in the signaling pathway. Treatment of scleroderma lung disease with cyclophosphamide may have a beneficial effect on pulmonary function and survival. Lung transplantation provides a therapeutic option for patients with scleroderma with end-stage lung disease.
- 1 March 2002
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 4 (2) , 108-112
Evaluation and management of pulmonary fibrosis in scleroderma
Pulmonary fibrosis causes significant morbidity and mortality in patients with scleroderma. Lung inflammation identifies patients at greater risk for decline in forced vital capacity and diffusing capacity for carbon monoxide. Factors that are increased in patients with scleroderma with lung fibrosis include connective tissue growth factor, KL-6, pulmonary surfactant-D, tissue inhibitor of metalloproteinase 2, monocyte chemotactic protein-1, macrophage inhibitory protein-1α, soluble interleukin-6 receptors, antiendothelial cell antibodies, and anti-DNA topoisomerase I antibodies. Potential mechanisms of lung damage in scleroderma include increased production of profibrotic type 2 cytokines and abnormal signaling by thrombin of tenascin-C production by lung fibroblasts, with protein kinase Cε as an intermediate in the signaling pathway. Treatment of scleroderma lung disease with cyclophosphamide may have a beneficial effect on pulmonary function and survival. Lung transplantation provides a therapeutic option for patients with scleroderma with end-stage lung disease.
- 1 February 2002
- Published by Springer Nature in Inflammation Research
- Vol. 51 (2) , 73-75
International society for rheumatic therapy guest society symposium: Recent therapeutic experiences with new generation drugs for inflammatory diseases
- 1 February 2002
- Published by Springer Nature in Inflammation Research
- Vol. 51 (2) , 73-75
International society for rheumatic therapy guest society symposium: Recent therapeutic experiences with new generation drugs for inflammatory diseases